13,948 Shares in Dianthus Therapeutics, Inc. $DNTH Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 13,948 shares of the company’s stock, valued at approximately $575,000.

Other hedge funds also recently added to or reduced their stakes in the company. Patient Square Capital LP bought a new position in Dianthus Therapeutics in the third quarter worth approximately $4,919,000. Vanguard Group Inc. raised its stake in Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares in the last quarter. UBS Group AG raised its stake in Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after buying an additional 469,547 shares in the last quarter. SG Americas Securities LLC bought a new position in Dianthus Therapeutics in the fourth quarter worth approximately $765,000. Finally, Fairmount Funds Management LLC raised its stake in Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after buying an additional 600,000 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DNTH has been the subject of a number of recent research reports. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Wolfe Research assumed coverage on Dianthus Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $98.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price on the stock. Finally, Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $93.01 on Friday. The stock has a market cap of $5.08 billion, a PE ratio of -22.52 and a beta of 1.18. The stock has a 50-day moving average of $86.80 and a two-hundred day moving average of $62.07. Dianthus Therapeutics, Inc. has a one year low of $16.64 and a one year high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, CEO Marino Garcia sold 122,918 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the completion of the transaction, the executive vice president directly owned 8,224 shares of the company’s stock, valued at approximately $738,844.16. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,021 shares of company stock worth $26,564,008 in the last quarter. 3.02% of the stock is currently owned by company insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.